Amitiza lubiprostone regulatory update

Sucampo and Takeda submitted an sNDA to FDA for Amitiza lubiprostone to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain. The partners requested Priority Review. Sucam...